Trial Profile
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of SU011248 in the Treatment of Patients With Imatinib Mesylate (Gleevec, Glivec)-Resistant or Intolerant Malignant Gastrointestinal Stromal Tumor.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Jun 2020
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Registrational; Therapeutic Use
- 10 Jun 2020 Results (n=350) of simulation study from four clinical trials: study 1004, study 1047, study 1045 and study 013 assessing effects of dose increase on pharmacodynamic biomarkers can increase OS and retaining an acceptable safety profile published in the Clinical Cancer Research
- 29 Sep 2009 Actual end date changed from 10 Oct 2006 to 1 May 2008 as reported by ClinicalTrials.gov (NCT00075218).
- 29 Sep 2009 Actual end date changed from 10 Oct 2006 to 1 May 2008 as reported by ClinicalTrials.gov (NCT00075218).